Ketamine Therapy in Arkansas

Ketamine therapy in Arkansas is governed by a combination of federal and state regulations that establish how the drug may be legally administered in clinical settings. At the federal level, ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning its use is permitted for legitimate medical purposes but requires strict oversight. Providers in Arkansas who administer ketamine must hold a valid DEA registration, and clinics must maintain detailed records of all controlled substance transactions in compliance with DEA requirements. The Arkansas State Medical Board oversees the licensure and conduct of physicians who prescribe or supervise ketamine infusion therapy, and only licensed medical professionals operating within their authorized scope of practice may administer or directly supervise ketamine treatments.

In Arkansas, ketamine infusion therapy is legal when administered by a qualified medical professional in a supervised clinical setting. The most established and widely accepted application is its FDA-approved use as an anesthetic agent. However, many clinics also offer ketamine infusions for off-label purposes, including treatment-resistant depression, PTSD, chronic pain, and anxiety disorders. Off-label use is legal and common in medical practice, but it places additional responsibility on the prescribing physician to ensure informed consent is obtained and that patients are thoroughly evaluated before treatment begins. The Arkansas State Board of Pharmacy also plays a regulatory role, overseeing the handling, dispensing, and storage of ketamine at licensed facilities.

Patients and providers in Arkansas should also be aware of the regulatory distinctions between IV ketamine infusions and esketamine (Spravato), the FDA-approved nasal spray form of ketamine used for treatment-resistant depression. Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA, which requires that it be administered only in certified healthcare settings where patients can be monitored for at least two hours following each dose. Key regulatory considerations for Arkansas ketamine providers include:

• Valid DEA Schedule III controlled substance registration for all prescribing providers
• Compliance with Arkansas State Medical Board standards for patient care and documentation
• Proper informed consent procedures, particularly for off-label ketamine applications
• Adherence to Arkansas State Board of Pharmacy rules for controlled substance storage and dispensing
• Enrollment in the Spravato REMS program for any clinic offering esketamine nasal spray
• Maintenance of accurate and complete medical records for all ketamine patients